NCT06119347View on ClinicalTrials.gov

Acute Kidney Injury in Cancer Patients Receiving Anti-Vascular Endothelial Growth Factor Monoclonal Antibody vs Immune Checkpoint Inhibitors

CompletedOBSERVATIONAL

Enrollment

1,581

Participants

Timeline

Start Date

January 1, 2020

Primary Completion Date

June 30, 2023

Study Completion Date

October 10, 2023

Conditions

AKI Incidence of Cancer Patients Receiving AntiVEGF or ICIs

Interventions

DRUG

AntiVEGF

anti-vascular endothelial growth factor monoclonal antibody drug includes bevacizumab;

DRUG

ICIs

immune checkpoint inhibitors include Pembrolizumab, Sintilimab, toripalimab, Camrelizumab, Tislelizumab.

Trial Locations (1)

325000

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou

All Listed Sponsors

lead

First Affiliated Hospital of Wenzhou Medical University

OTHER

NCT06119347 - Acute Kidney Injury in Cancer Patients Receiving Anti-Vascular Endothelial Growth Factor Monoclonal Antibody vs Immune Checkpoint Inhibitors | Biotech Hunter | Biotech Hunter